Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks

Clinical and Vaccine Immunology

Volumn 21, Issue 1, 2014, Pages 66-73

  Chen, Wilbur H ^a   Greenberg, Richard N ^b   Pasetti, Marcela F ^a   Livio, Sofie ^a   Lock, Michael ^c   Gurwith, Marc ^c   Levine, Myron M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c PaxVax Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; CHOLERA VACCINE; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; MUTACOL; PLACEBO; SHANCHOL; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIBODY SPECIFICITY; ARTICLE; ASTHENIA; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FECES LEVEL; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; LOOSE FECES; MALE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SEROCONVERSION; SINGLE DRUG DOSE; VACCINATION; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL SHEDDING; BLOOD BACTERICIDAL ACTIVITY; CHOLERA VACCINES; FECES; HUMANS; IMMUNOGLOBULIN G; MALE; PLACEBOS; TIME FACTORS; VACCINATION; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84892158051     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00601-13     Document Type: Article

References (39)

1. Lantagne D, Balakrish Nair G, Lanata CF, Cravioto A. 2013. The cholera outbreak in Haiti: where and how did it begin? Curr. Top. Microbiol. Immunol., in press. http://dx.doi.org/10.1007/82-2013-331.
2. Steffen R, Acar J, Walker E, Zuckerman J. 2003. Cholera: assessing the risk to travellers and identifying methods of protection. Travel Med. Infect. Dis. 1: 80-88. http://dx.doi.org/10.1016/S1477-8939(03)00062-0.
3. Newton AE, Heiman KE, Schmitz A, Török T, Apostolou A, Hanson H, Gounder P, Bohm S, Kurkjian K, Parsons M, Talkington D, Stroika S, Madoff LC, Elson F, Sweat D, Cantu V, Akwari O, Mahon BE, Mintz ED. 2011. Cholera in United States associated with epidemic in Hispaniola. Emerg. Infect. Dis. 17: 2166-2168. http://dx.doi.org/10.3201/eid1711.110808.
4. Charles RC, Ryan ET. 2011. Cholera in the 21st century. Curr. Opin. Infect. Dis. 24: 472-477. http://dx.doi.org/10.1097/QCO.0b013e32834a88af.
5. Levine MM, Kaper JB. 1995. Live oral cholera vaccine: from principle to product. B. I. Pasteur 93: 243-253. http://dx.doi.org/10.1016/0020-2452(96) 85758-7.
6. Calain P, Chaine JP, Johnson E, Hawley ML, O'Leary MJ, Oshitani H, Chaignat CL. 2004. Can. oral cholera vaccination play a rolein controlling a cholera outbreak? Vaccine 22: 2444-2451. http://dx.doi.org/10.1016/j.vaccine. 2003.11.070.
7. Levine MM, Herrington D, Losonsky G, Tall B, Kaper JB, Ketley J, Tacket CO, Cryz S. 1988. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 2: 467-470.
8. Ketley JM, Michalski J, Galen J, Levine MM, Kaper JB. 1993. Construction of genetically marked Vibrio cholerae O1 vaccine strains. FEMS Microbiol. Lett. 111: 15-21. http://dx.doi.org/10.1111/j.1574-6968.1993.tb06355.x.
9. Kaper JB, Levine MM. 1990. Recombinant attenuated Vibrio cholerae strains used as live oral vaccines. Res. Microbiol. 141: 901-906. http://dx.doi.org/10. 1016/0923-2508(90)90128-D.
10. Mosley WH, Ahmad S, Benenson AS, Ahmed A. 1968. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull. World Health Organ. 38: 777-785.
11. Mosley WH, Benenson AS, Barui R. 1968. A serological survey for cholera antibodies in rural east Pakistan. 2. A comparison of antibody titres in the innunized [sic] and control populationd [sic] of a choleravaccine field-trial area and the relation of antibody titre to cholera case rate. Bull. World Health Organ. 38: 335-346.
12. Glass RI, Svennerholm AM, Khan MR, Huda S, Huq MI, Holmgren J. 1985. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J. Infect. Dis. 151: 236-242. http://dx.doi.org/10.1093/infdis/151.2.236.
13. Levine MM, Kaper JB, Herrington D, Losonsky G, Morris JG, Clements ML, Black RE, Tall B, Hall R. 1988. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect. Immun. 56: 161-167.
14. Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, Edelman R, Kaper JB, Cryz SJ, Giannella RA, Schiff G, Levine MM. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect. Immun. 67: 6341-6345.
15. Sack DA, Shimko J, Sack RB, Gomes JG, MacLeod K, O'Sullivan D, Spriggs D. 1997. Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers. Infect. Immun. 65: 2107-2111.
16. Sack DA, Clemens JD, Huda S, Harris JR, Khan MR, Chakraborty J, Yunus M, Gomes J, Siddique O, Ahmed F, Kay BA, van Loon FPL, Rao MR, Svennerholm AM, Holmgren J. 1991. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J. Infect. Dis. 164: 407-411. http://dx.doi.org/10.1093/infdis/164.2.407.
17. Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, Qadri F. 2011. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 29: 8285-8292. http://dx.doi.org/10.1016/j.vaccine.2011.08.108.
18. Kotloff KL, Wasserman SS, O'Donnell S, Losonsky GA, Cryz SJ, Levine MM. 1992. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect. Immun. 60: 4430-4432.
19. Su-Arehawaratana P, Singharaj P, Taylor DN, Hoge C, Trofa A, Kuvanont K, Migasena S, Pitisuttitham P, Lim YL, Losonsky G, Kaper JB, Wasserman SS, Cryz S, Echeverria P, Levine MM. 1992. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J. Infect. Dis. 165: 1042-1048. http://dx.doi.org/10. 1093/infdis/165.6.1042.
20. Gotuzzo E, Butron B, Seas C, Penny M, Ruiz R, Losonsky G, Lanata CF, Wasserman SS, Salazar E, Kaper JB. 1993. Safety, immunogenicity, and excretion patternofsingle-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun. 61: 3994-3997.
21. Suharyono, Simanjuntak C, Totosudirjo H, Witham N, Punjabi N, Burr D, Sorenson K, Heppner DG, Losonsky G, Clemens J, Lim YL, Wasserman SS, Kaper J, Levine MM, Rifai AR, Cryz S. 1992. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 340: 689-694. http://dx.doi.org/10.1016/0140-6736(92)92231-4.
22. Lagos R, Avendaño A, Prado V, Horwitz I, Wasserman S, Losonsky G, Cryz S, Kaper JB, Levine MM. 1995. Attenuated live cholera vaccine strain CVD 103-Hgr elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect. Immun. 63: 707-709.
23. Simanjuntak CH, O'Hanley P, Punjabi NH, Noriega F, Pazzaglia G, Dykstra P, Kay B, Suharyono, Budiarso A, Rifai AR, Wasserman SS, Losonsky G, Kaper J, Cryz S, Levine MM. 1993. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J. Infect. Dis. 168: 1169-1176. http://dx.doi.org/10.1093/ infdis/168.5.1169.
24. Lagos R, San Martin O, Wasserman SS, Prado V, Losonsky GA, Bustamante C, Levine MM. 1999. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers. Pediatr. Infect. Dis. J. 18: 624-630. http://dx.doi.org/10.1097/00006454-199907000-00011.
25. Perry RT, Plowe CV, Koumaré B, Bougoudogo F, Kotloff KL, Losonsky GA, Wasserman SS, Levine MM. 1998. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull. World Health Organ. 76: 63-71.
26. Tacket CO, Losonsky G, Nataro JP, Cryz SJ, Edelman R, Kaper JB, Levine MM. 1992. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 166: 837-841. http://dx.doi.org/10.1093/infdis/166.4.837.
27. Levine MM, Kaper JB. 1993. Live oral vaccines against cholera: an update. Vaccine 11: 207-212. http://dx.doi.org/10.1016/0264-410X(93)90019-T.
28. Cohen MB, Giannella RA, Bean J, Taylor DN, Parker S, Hoeper A, Wowk S, Hawkins J, Kochi SK, Schiff G, Killeen KP. 2002. Randomized, controlled human challenge study ofthe safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect. Immun. 70: 1965-1970. http://dx.doi.org/10.1128/IAI.70.4.1965-1970.2002.
29. Rennels MB, Levine MM, Daya V, Angle P, Young C. 1980. Selective vs. nonselective media and direct plating vs. enrichment technique in isolation of Vibrio cholerae: recommendations for clinical laboratories. J. Infect. Dis. 142: 328-331. http://dx.doi.org/10.1093/infdis/142.3.328.
30. Benenson AS, Saad A, Mosley WH. 1968. Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique. Bull. World Health Organ. 38: 277-285.
31. Levine MM, Young CR, Black RE, Takeda Y, Finkelstein RA. 1985. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J. Clin. Microbiol. 21: 174-179.
32. Hochberg Y. 1988. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75: 800-802. http://dx.doi.org/10.1093/biomet/75.4.800.
33. Snyder JD, Allegra DT, Levine MM, Craig JP, Feeley JC, DeWitt WE, Blake PA. 1981. Serologic studies of naturally acquired infection with Vibrio cholerae serogroup O1 in the United States. J. Infect. Dis. 143: 182-187. http://dx.doi.org/10.1093/infdis/143.2.182.
34. Blake PA, Allegra DT, Snyder JD, Barrett TJ, McFarland L, Caraway CT, Feeley JC, Craig JP, Lee JV, Puhr ND, Feldman RA. 1980. Cholera - a possible endemic focus in the United States. N. Engl. J. Med. 302: 305-309. http://dx.doi.org/10.1056/NEJM198002073020601.
35. Levine MM. 2010. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 8: 129. http://dx.doi.org/10.1186/1741-7007-8-129.
36. Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, Lesmana MM, Wangsasaputra FF, Pandam SS, Levine MM, O'Hanley PP, Cryz SJ, Simanjuntak CH. 2000. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, In-donesia, acholera-endemic area. Vaccine 18: 2399-2410. http://dx.doi.org/10.1016/S0264-410X(00)00006-2.
37. Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M, Holmgren J, Clemens JD. 2005. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366: 44-49. http://dx.doi.org/10.1016/S0140- 6736(05)66550-6.
38. Clemens JD, Harris JR, Sack DA, Chakraborty J, Ahmed F, Stanton BF, Khan MU, Kay BA, Huda N, Khan MR, Yunus M, Rao MR, Svennerholm AM, Holmgren J. 1988. Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J. Infect. Dis. 158: 60-69. http://dx.doi.org/10.1093/infdis/158.1. 60.
39. Longini IM, Jr, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD. 2007. Controlling endemic cholera with oral vaccines. PLoS Med. 4:e336. http://dx.doi.org/10.1371/journal.pmed.0040336.